Massive ovarian cancer screening trial tests whether early detection cuts deaths

NCT ID NCT01696994

Ongoing Knowledge-focused Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study enrolled over 78,000 women to see if regular screening with ultrasound and blood tests can lower the number of deaths from ovarian cancer. Participants were randomly assigned to either receive screening or usual care. The goal is to find out if catching the cancer early helps women live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could show that regular screening reduces deaths from ovarian cancer, leading to better early detection guidelines.
What could go wrong: This trial is observational and completed enrollment; screening may not reduce deaths and could lead to false alarms or unnecessary procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma ovarian germ cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CARCINOMA OVARIAN GERM CELL TUMOR

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.